Venetoclax + Fludarabine/Busulfan conditioning + post-transplant maintenance

Current understanding

A phase I/II trial is evaluating venetoclax added to the standard fludarabine + busulfan (FluBu) conditioning backbone prior to allogeneic stem cell transplant, followed by post-transplant maintenance with venetoclax combined with either azacitidine or oral decitabine/cedazuridine (ASTX727). The population includes AML, MDS, CMML, and MDS/MPN-unclassifiable, extending the established HMA + BCL-2 inhibitor paradigm into both the peri-transplant conditioning and maintenance windows. Evidence is currently trial-early with safety as the primary endpoint.

Evidence log

Open questions

Related